BRISTOL, Tenn. and SAN MATEO, Calif., Dec. 27, 2010 (GLOBE NEWSWIRE) -- King Pharmaceuticals®, Inc. (NYSE:KG) and Pain Therapeutics®, Inc. (Nasdaq:PTIE) today announced that King has resubmitted a New Drug Application (NDA) for REMOXY® (oxycodone) to the U.S. Food and Drug Administration (FDA) in response to a Complete Response letter received by Pain Therapeutics in December 2008. This is a Class 2 resubmission with a six month review cycle.
